Researchers at the University of Notre Dame are fighting to discover compounds and develop drugs to treat neglected diseases that affect billions of the world’s most vulnerable people.

This is why we study organic chemistry. This is why we do research. Every 20 seconds, someone dies from tuberculosis (TB), yet it’s been over 40 years since a new TB drug has been approved for use. Why? Because doing so wasn’t viewed as economically viable. Tell that to the more than two billion people—mostly the developing world’s sick and poor—infected with the bacterium that causes TB, a bacterium that is becoming increasingly drug-resistant to current treatments.

Through the discovery of a unique molecular compound, Marvin Miller, the George and Winifred Clark Chair in Chemistry, has made a significant scientific breakthrough in the potential treatment of tuberculosis. Now, in an innovative private-public partnership, Prof. Miller and his team of interdisciplinary researchers from Notre Dame (Garrett Moraski ’97, Lowell Markley, and Prof. Jeffrey Schorey) are working with partners like the Lilly TB Drug Discovery Initiative and Hsiri Therapeutics to transition their discovery into an affordable, anti-tuberculosis treatment for patients in underdeveloped countries.

The University of Notre Dame asks you, “What would you fight for?” Learn more about this research and how to support it.